$BEATW News

HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP)

HEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam Technology

HeartBeam stock soars on FDA breakthrough designation

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

HeartBeam Receives FDA Breakthrough Device Designation For Its HeartBeam System For Assessing Potential Heart Attacks At Home

HC Wainwright & Co. Downgrades HeartBeam to Neutral

HeartBeam, Inc. Letter to Shareholders

HeartBeam Enters ATM Equity Offering Agreement To Sell Up To $25M Of Common Stock Through Titan Partners Securities

HeartBeam, Inc. Q2 2026 Earnings Call Summary

HeartBeam Inc (BEAT) (Q2 2026) Earnings Call Highlights: FDA Submission Advances and Commercial ...

HeartBeam Reports Second Quarter 2026 Results

HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

Maxim Group Initiates Coverage On HeartBeam with Buy Rating, Announces Price Target of $2

HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

HeartBeam Wins U.S. Patent Expanding ECG Device With Acoustic Sensing, Impedance Features For Heart Disease Monitoring

HeartBeam (BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule

HeartBeam (BEAT) Completes Enrollment Ahead of Schedule in Heart Attack Detection Pilot Study